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1GLOSSARY OF ABBREVIATIONS
ACMG/AMP American College of Medical Genetics and Genomics and Association for Molecular
Pathology
AS Alternative splicing
ASEs Alternative splicing events
cDNA Complementary DNA
C-terminal     Carboxyl-terminal
DCM Dilated cardiomyopathy
FN3 Fibronectin type III domain
gDNA Genomic DNA
HMERF Hereditary myopathy with early respiratory failure
hnRNPs Heterogeneous nuclear ribonucleoproteins
Ig Immunoglobulin-like
IGV Integrative Genomics Viewer
kb Kilobase
LB Lysogeny broth
LOF Loss of function
Mdm Muscular dystrophy with myositis
MARPs Muscle ankyrin repeat proteins
Murf2 Muscle-specific RING finger protein 2
NCBI National center for biotechnology information
NGS Next-generation sequencing
NMD Non-Sense Mediated Decay
N-terminal     Amino-terminal
PEVK Proline, glutamic acid, valine, lysine
PKG Protein kinase G
Poly (A) Polyadenylation
Poly (E) Glutamic acid chain
2PPAK Proline, proline, alanine, lysine
PSI Percent/proportion spliced in
PTC Premature termination codon
RBM20 RNA-binding motif protein 20
RNA-Seq RNA sequencing
RPM Revolutions per minute
RT Reverse transcription
SH3 domain Src homology-3 domain
SMRT Single molecule real time sequencing
SNP Single nucleotide polymorphism
snRNA Small nuclear RNA
SNVs Single nucleotide variants
SRF Serum response factor
S100A1 S100 calcium-binding protein A1
TK Titin kinase
TTN Titin gene
TTNtv Titin truncating variant
UTR Untranslated region
VUS Variant of uncertain significance
WT Wild type
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The TTN gene (cytogenetic location 2q31.2) encodes a giant muscle protein called titin that
extends from Z-disc to M-band within the sarcomere and functions as a molecular spring during
sarcomere contraction, relaxation and extension (Linke 2000) (Figure 1a and 1b). With a colossal
size of approximately 300 kilobase (kb) pairs and 363 coding exons (Bang, Centner et al. 2001) (by
far the most exons in any gene), TTN codes for the largest known protein to date and via
alternative splicing can theoretically produce more than a million splice variants (Guo, Bharmal et
al. 2010). However, only seven main human TTN isoforms have been reported according to the
NCBI RefSeq transcript/nucleotide database.
Titin is primarily expressed in skeletal and cardiac muscles, but its expression has been reported in
non-muscle and smooth muscle cells with some distinctive structural and interactive features than
those of skeletal and cardiac titins (Keller, Eilertsen et al. 2000). The variability among titin
isoforms is considerably high, and tissue-specific isoforms also exist (Guo, J Bharmal et al. 2010).
Moreover, RNA sequences from cardiac samples have unraveled the presence of different
isoforms within the same tissue (Roberts, Ware et al. 2015). All titin isoforms are approximately
27000 – 36000 amino acid residues long except the Novex 3 isoform that is merely composed of
5604 amino acid residues (Linke 2018). Clinically, a broad range of neuromuscular disorders,
including skeletal and cardiac muscle disorders are ascribed to defects in TTN gene (Savarese,
Sarparanta et al. 2016).
Neuromuscular disorders encompass a broad spectrum of genetically heterogeneous conditions
that affect muscles. Gene table of neuromuscular disorders (musclegenetable.fr) reports 535
different genes associated with neuromuscular disorders out of which approximately 100 genes
are mutated in primary myopathies. In routine diagnostics, traditional sequencing methods are
not adequate to analyze patients with less characterized phenotypes that require sequencing of a
vast number of genes including some very large genes such as TTN, NEB (codes for nebulin), etc in
order to make an accurate diagnosis. However, this obstacle has been overcome with the advent
of Next-Generation Sequencing (NGS), which allows hundreds of genes to be sequenced in a single
batch (Schrijver, Aziz et al. 2012). Previously our group had developed a targeted NGS panel called
4MyoCap, which contained exon and untranslated region (UTR) sequences of 180 genes pertinent
to different myopathies (Evila, Arumilli et al. 2016). Later versions of MyoCap are upgraded with
exon sequences of around 300 myopathy and muscular dystrophy-related genes, including UTR
and intronic sequences of certain genes.
In spite of powerful sequencing technologies, the consequences of splicing mutations are better
comprehended with transcriptome studies. In this project, we applied RNA and different cDNA
sequencing techniques for characterization of specific splicing mutations detected in NGS MyoCap
assay to discern whether a particular splicing variant/variant of uncertain significance (VUS) is
benign or causative. The other variants in trans were not further included in this study as they
were already predicted to be pathogenic according to the guidelines of American College of
Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP).
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2.1 THE STRUCTURE AND FUNCTION OF TITIN
A single titin molecule is more than 1 μm in length and covers half of a sarcomere and regulates its
stability during muscle extension and contraction (Tskhovrebova and Trinick 2010). The titin
molecules run antiparallel to each other in a sarcomere, and the last few amino acids of N- termini
of titins overlap in adjacent sarcomeres and within a sarcomere titin polypeptides overlap in their
C-termini (Figure 1a), hence forming a consecutive filament array in myofibrils (McElhinny,
Kakinuma et al. 2002). Being the third most abundant muscle protein after myosin and actin
(Kellermayer, Smith et al. 2017), titin also serves as a molecular hub for signal transduction and a
scaffold protein, harboring several binding sites for other proteins and aiding in myofibrillar
assembly (Krüger and Kötter 2016).
The structure of titin is highly modular and comprised of four parts, categorized on the basis of
their sarcomeric location, the amino-terminal (Z-disc anchored region), the I-band and A-band
regions and the carboxyl-terminal (M-band anchored region) (Meyer and Wright 2013).
Approximately 90% of titin is composed of Immunoglobulin-like domains (Ig domains) and
Fibronectin type III domains (FN3 domains) that are arranged predominantly in tandem repeats
(Toro, Olivé et al. 2013), the other 10% is shaped by Z repeats, a serine-threonine kinase domain,
PEVK domain and unique sequences.
6Sarcomere
Figure 1: (a) The antiparallel layout of titin filaments within a sarcomere, a single titin polypeptide spans half of a
sarcomere. (b) General depiction of how the elastic property of sarcomere is regulated by titin.
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72.1.1 TITIN Z-DISC
The Z-disc region of titin is situated in the N-terminal of the molecule and encoded by the first few
TTN exons. Two important Ig domains (Z1 and Z2) are positioned on the extreme N-terminal end
of the molecule where these domains from two individual titin molecules interact with telethonin
protein. The Z1 and Z2 domains are followed by unique sequence and Z repeat region (Figure 2).
The Z repeat is a 45 amino acids multiple motif (encoded by TTN exons 8-14) that binds with the C-
terminal region of α-Actinin, which crosslinks the actin filament to titin (Young, Ferguson et al.
1998, Linke 2008). The titin-telethonin interaction is highly resistant to mechanical forces during
sarcomere extension and together with Alpha-actinin plays a key role in providing structural
integrity to the Z-disc of sarcomere (Linke 2008).
Figure 2: The figure illustrates the interaction of N-termini of two titin molecules with telethonin from the same half
sarcomere.
Redrawn from http://www.ks.uiuc.edu/Research/telethonin/
2.1.2 TITIN I-BAND
The I-band region of titin (encoded by TTN exons 28-252, skipping exon 48 which is exclusive to
Novex 3 isoform only) is largely composed of proximal (near Z-disc) and distal (near A-band)
tandem Ig domains flanking a PEVK (Proline, Glutamic acid, Valine, Lysine) rich fragment with
unique sequences interspersed (Figure 3). Large macromolecular conformational changes take
8place in I-band upon relaxation and stretch (Meyer and Wright 2013). Additionally, force-induced
phosphorylation of titin at specific sites in I-band modifies the myofilament stiffness (Hamdani,
Herwig et al. 2017).
The PEVK domain, which is an epitome of molecular elastic, contains repeating motifs of 26-28
residues, the positively charged PPAK motifs (Lysine abundant motifs) and the negatively charged
Poly (E) motifs (Glutamic acid abundant motifs). The opposite charges of motifs enable to
overcome repulsive forces and are hypothesized to be crucial for ionic interactions between two
classes of motifs (Greaser 2001).
The calcium-dependent endopeptidase calpain 1 binds to the proximal Ig domain of I-band
(Raynaud, Fernandez et al. 2005) while actin, which is one of the most abundant muscle proteins is
known to interact with PEVK segment and contributes to passive stiffness (Kulke, Fujita-Becker et
al. 2001). Another giant muscle protein nebulin interacts with titin PEVK segment through its SH3
domain (Ma and Wang 2002); however, the exact function of titin-nebulin interaction is obscure at
present (Chu, Gregorio et al. 2016). The Ig and PEVK domain in I-band collectively define the
elasticity property of titin (Trombitas, Greaser et al. 1998).
The I-band also contains two unique elements called N2A (4 Ig domains and 106 amino acids
unique sequence) and N2B (3 Ig domains and 572 amino acids unique sequence) (Cazorla, Freiburg
et al. 2000). The N2A region is expressed in both skeletal and cardiac muscles, while N2B is only
expressed in cardiac muscles (Labeit and Kolmerer 1995). The N2A region possesses binding sites
for muscle ankyrin repeat proteins (MARPs) that have a role in muscle stress-activated pathway
(Miller, Bang et al. 2003). Deletion of specific exons of N2A region disrupts a putative binding site
for calpain 3, which leads to muscular dystrophy with myositis (mdm) in mice (Garvey, Rajan et al.
2002).
Likewise, the N2B region contains a protein-protein interaction site for transcriptional co-regulator
called Four and Half LIM Domain 2 (FHL2), which might have role in directing metabolic enzymes
to high energy demand sites in cardiac sarcomere (Lange, Auerbach et al. 2002). A stress protein
AlphaB-crystallin (chaperone in nature) also interacts with N2B element. Studies in mouse have
shown that deletion of N2B element prompts diastolic dysfunction and cardiac atrophy (Radke,
Peng et al. 2007).
92.1.3 TITIN A-BAND
The A-band is the largest region of titin and is encoded by TTN exons 253-358. The structural
organization of A-band is highly repetitive of Ig-like domain and FN3 domain (Figure 3). Both of
these domain classes are arranged in 7 (D-zone) and 11 (C-zone) super repeats array, of which the
C-zone is more frequent with a pattern of Ig-Fn3-Fn3-Ig-Fn3-Fn3-Fn3-Ig-Fn3-Fn3-Fn3 repeats. The
A-band segment interacts with Myosin and Myosin binding protein-C, this ternary complex is
believed to be crucial for sarcomere thick-filament assembly (Freiburg and Gautel 1996, Tonino,
Kiss et al. 2017).
Contrary to I-band, the A-band region is relatively inextensible (Tskhovrebova and Trinick 2003).
The A-band fragment is under the influence of active and passive forces during sarcomere
extension and contraction, and the mechanical stress may subsequently trigger the titin signaling
events that modulate muscle hypertrophy (Lewartowski and Mackiewicz 2014).
Since A-band titin serves as a platform for interaction of sarcomere thick filament proteins, it is
characterized as a molecular ruler that governs the length of myosin filaments (Linke 2008).
Figure 3: General overview of different domains of titin in I-band and A-band. The N2A region (expressed in both
cardiac and skeletal muscles) and cardiac muscle specific N2B region are also shown.
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2.1.4 TITIN M-BAND
The M-band region of titin is encoded by the last 6 TTN exons (359-364/Mex1-Mex6) and
positioned in the C-terminal end of the molecule. In addition to Ig-like and FN3 domains, the M-
line titin includes an autoinhibitory serine/threonine kinase domain (Labeit, Gautel et al. 1992),
which inhibits its activation by C-terminal regulatory tail in the catalytic subdomain that intercepts
the ATP binding; thus, titin kinase (TK) remains inactivated in a relaxed sarcomere. The mechanical
force transmission removes the steric blockage of ATP binding site followed by
autophosphorylation of a tyrosine residue that ultimately activates TK (Puchner, Alexandrovich et
al. 2008) (Figure 4).
TK in its activated state interacts with numerous proteins including MURF2 and couples a
signalosome. In the absence of mechanical stress, the signalosome is disengaged, and MURF2 is
translocated to the nucleus where it can interact with a transcription factor called serum response
factor (SRF) and hamper its transcriptional regulation activity. Hence, force-induced TK activation
keeps the MURF2 out of the nucleus and augments the SRF-dependent muscle gene expression
(Gautel 2011).
Titin M-band is also essential for sarcomere structural integrity and myofibril formation.
Homozygous deletion of titin M-band results in failure of cardiac progenitor cells to differentiate
and precludes sarcomerogenesis (Musa, Meek et al. 2006). Besides its significance in signaling and
muscle development, mutations in titin M-band are linked to various neuromuscular disorders
(Udd, Vihola et al. 2005, Carmignac, Salih et al. 2007, Chauveau, Bonnemann et al. 2014).
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Figure 4: The figure encapsulates stepwise activation of titin kinase domain via autophosphorylation induced by
mechanical force. Step 1: The ATP binding site is blocked by C-terminal regulatory tail in a relaxed sarcomere. Step 2:
The mechanical force disengages C-terminal regulatory tail, exposing the site for ATP binding. Step 3: The ATP binding
autophosphorylates tyrosine and activates TK.
Redrawn from (Puchner, Alexandrovich et al. 2008).
2.2 ALTERNATIVE SPLICING
Alternative splicing (AS) is a post-transcriptional process whereby a single gene encodes for
multiple protein isoforms. In constitutive splicing, introns are discarded and exons are ligated in
the order they are arranged in a gene. AS is a diversion from the arranged order of exons in a
gene, resulting in a distinct pattern of exon-exon junctions in mature mRNA. Hence, AS is a major
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source of escalating proteome diversity and its functional complexity (Liu, Gonzalez-Porta et al.
2017).
The splicing is highly influenced by the 5’ splice site sequence, branch point sequence and 3’ splice
site sequence (Wang and Burge 2008). The branch point sequence is located few nucleotides
upstream of the 3’ end of intron and has a consensus sequence of “YUNAY” (Y=Cytosine/
Thymine, N=any nucleotide) where A serves as branch site and along with U is well conserved
(Gao, Masuda et al. 2008). Statistical analysis of 22,489 splice junction pairs from GenBank 
database showed that 98.71% of splice junction sequences are 5’ GT (donor site) and 3’ AG
(acceptor site) and are termed canonical splice sites, whereas 0.56% of splice junction pairs con-
tain major non-canonical GC-AG as donor and acceptor sites. Lastly, the remaining 0.73% of
splice site pairs contain multiple distinct non-canonical splice sites (Burset, Seledtsov et al. 2000).
Spliceosomes are large ribonucleoprotein structures that catalyze splicing. The major spliceosome
is assembled from small nuclear RNAs (snRNAs) U1, U2, U4, U5, U6 and around 300 different
proteins (Nilsen 2003). In addition, trans-acting splicing elements i.e. serine and arginine-rich (SR)
proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) have a critical role in splicing
regulation (Anna and Monika 2018). One of the well-studied splicing regulators is RMB20. A study
details the role of RBM20 (RNA binding motif protein 20) as a TTN splicing repressor in rats and
humans. RBM20 deficiency results in unusually large titin isoform expression and is implicated in
dilated cardiomyopathy (Guo, Schafer et al. 2012).
Mutations can impair canonical splice sites, generate new splice sites and activate cryptic splice
sites. Moreover, the mutations in cis-regulatory elements such as exon and intron splicing
enhancers and silencers may result in deviation from the normal splicing pathway (Anna and
Monika 2018). To cope with aberrant splicing pathway to a certain extent, the cellular machinery
has an excellent surveillance mechanism called non-sense mediated decay (NMD), which targets
the mRNA transcripts for degradation if they harbor a premature termination codon (PTC).
However, NMD is inefficient if the PTC is located in the last exon and the efficiency of NMD also
decreases if PTC is present few nucleotides upstream of the last exon (Lindeboom, Supek et al.
2016).
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It has been estimated by a compendium of splice/exon-exon junctions analyzed from RNA-Seq
data that approximately 90% of all multi-exon human genes undergo alternative splicing, many in
tissue and/or developmental stage-specific manner (Pan, Shai et al. 2008, Wang, Sandberg et al.
2008).
Exon skipping is the most prevalent mechanism of alternative splicing, which either eliminates 
or retains a particular exon from pre-mRNA. Other modes of AS are use of alternative 5´ or 3´ 
splice site (ASS) (partial exclusion of exon), mutually exclusive exons (one of the two adjacent 
exons is retained), intron retention (intronic sequence remains intact), use of alternative 
polyadenylation sites (different exon at 3´ of transcript) (Figure 5a) alternative promoter selec-
tion (isoforms with differing translation start sites) (Keren, Lev-Maor et al. 2010) (Figure 
5b). The alternative polyadenylation mode also influences translation and isoform turnover rate 
based on the length of 3´UTR and poly (A) tail (Tanguay and Gallie 1996). In addition, com-
plex alternative splicing patterns also occur in a transcript (multiple alternative splicing events
[ASEs] in a single pre-mRNA molecule) that can generate thousands of splicing variants (Park, Pan 
et al. 2018) (Figure 5c).
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Figure 5: (a) General examples of various modes of alternative splicing. (a) and (b) Rectangles and bars colored light
blue represent segments spliced in, whereas rectangles and bars colored black represent segments discarded from
final transcript. (b) Alternative promoter selection is an indirect pattern of splicing; if promoter 1 is used as
transcription start site, the splicing machinery has to scission the following promoter because acting as a 5’ terminal
exon (1st exon) of Promoter 1 it lacks 3’ splice site and cannot be recognized by splicing factors. (c) Intricate patterns of
splicing e.g. splicing pattern 2 (sp2) is a combination of partial exon exclusion and partial intron retention.
Redrawn from (Srebrow and Kornblihtt 2006) and (Park, Pan et al. 2018).
a
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Since most multi-exon genes produce multiple isoforms, one of the many isoforms is generally
regarded as canonical isoform on the basis of expression, length, etc. Despite being transcribed
from a single gene, many isoforms are functionally disparate (Li, Menon et al. 2014). Moreover, an
isoform may execute an antagonistic effect or a dominant-negative effect, i.e. two isoforms
of BCL2L1 gene have opposite functions in apoptosis; the longer isoform impedes the process
while the shorter isoform promotes apoptosis (Boise, Gonzalez-Garcia et al. 1993).
2.2.1 TITIN ISOFORMS AND SPLICING VARIANTS
TTN contains 364 exons, of them 363 are coding except the very first non-coding exon. This
enormous number of exons in contrast to around 8-10 exons, which is an average number of 
exons in human genes (Sakharkar, Chow et al. 2004) enables TTN to generate thousands of 
splicing variants through differential splicing.
NCBI RefSeq transcript database lists seven main titin isoforms and none of them contain all 364
exons (Table 1). Titin isoforms are a result of alternative splicing principally in I-band region. In
contrast, the Z-disc, A-band and-M-band sections are largely conserved among different isoforms
(Labeit and Kolmerer 1995).
Generally, titin isoforms are classified on the basis of presence of skeletal muscle-specific N2A
element and cardiac muscle-specific N2B element in the I-band region, and N2BA that co-
expresses both elements in cardiac muscles. Furthermore, some TTN exons are skipped in all
isoforms except the all-inclusive meta transcript isoform (skips exon 48 only), which is speculated
to be expressed only during prenatal life (Savarese, Jonson et al. 2018).
The N2A and N2BA isoforms retain most of the I-band exons, whereas the splicing pathway in N2B
isoform splices exon 50 to exon 220; thereby skipping many Ig-like domains, PEVK domains and
unique sequence encoding exons of I-band (Linke 2008). The N2B isoform has less extensible
potential due to its relatively shorter I-band (Cazorla, Freiburg et al. 2000) and the average
expression ratio of N2BA:N2B is around 30:70. However, due to the up-regulation of N2BA in
dilated cardiomyopathy the average N2BA:N2B ratio is approximately 42:58 in DCM patients
which consequently lessens the passive myocardial stiffness (Makarenko, Opitz et al. 2004).
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Conversely, cardiac passive stiffness increases during postnatal development when fetal cardiac
titin expression is superseded by adult cardiac titin isoforms (Lahmers, Wu et al. 2004).
Three additional cardiac titin isoforms are produced via mutually exclusive splicing mode, namely
Novex 1 (exon 45), Novex 2 (exon 46) and Novex 3 (exon 48) (Bang, Centner et al. 2001). The
Novex 1 and Novex 2 are identical to N2B isoform with the additional inclusion of 125 (Exon 45)
and 192 (Exon 46) unique amino acid sequences in I-band region, respectively (Savarese,
Sarparanta et al. 2016). The ‘tiny titin’ Novex 3 is the only isoform that retains exon 48, which
contains alternate termination codon resulting in proportionately small 700 kDa protein with
alternative C-terminal (Bang, Centner et al. 2001). Moreover, an additional isoform called Cronos
that is produced with an alternative promoter from I-band has also been reported and linked as a
likely contributor to severe cardiomyopathy phenotype (Deo 2016).
RNA-Seq data obtained from left ventricle biopsies of DCM patients and anatomically different
skeletal muscle biopsies showed that some exons are constitutively expressed while few exons are
inconsistently incorporated in a particular isoform (Roberts, Ware et al. 2015, Savarese, Jonson et
al. 2018). This differential exon usage is measured as PSI value (percent/proportion spliced in) that
estimates the mean value of a specific exon inclusion in mature transcripts; the higher PSI refers to
frequent exon usage and vice versa (Roberts, Ware et al. 2015).
To some extent, TTN structure is appropriate for extensive alternative splicing as 85% of the TTN
exons are symmetric (entire exon sequence is in triplets) and their removal does not render
frameshift effect. To a certain extent the PSI corresponds to exon symmetry, for instance, 49 of
185 exons with PSI >99% are asymmetric. Furthermore, the lowest PSI value is observed in TTN
I- band region where 93% of alternatively spliced exons are symmetric (Roberts, Ware et al. 2015).
The higher PSI in asymmetric exons is likely to be favorable owing to the fact that asymmetric exon
exclusion can distort translation reading frame.
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Table 1: The table of seven main human TTN isoforms.
(Modified from https://www.cardiodb.org/titin/titin_transcripts.php and updated according to
NCBI nucleotide database)
Isoform Description Transcript
Length
(Excluding
5´ cap and
poly (A)
tail)
Polypeptide
Length
Number
of Exons
Refseq
Transcript
Refseq Protein
Meta Complete
meta
transcript
109224 35991 363 NM_0012675
50.2
NP_00125447
9.2
N2BA Principle
cardiac long
isoform
104301 34350 313 NM_0012568
50.1
NP_00124377
9.1
N2A Soleus/
skeletal long
isoform
101520 33423 312 NM_133378.
4
NP_596869.4
N2B Principle
cardiac short
isoform
82029 26926 191 NM_003319.
4
NP_003310.4
Novex 1 Minor cardiac
short isoform
82404 27051 192 NM_133432.
3
NP_597676.3
Novex 2 Minor cardiac
short isoform
82605 27118 192 NM_133437.
4
NP_597681.3
Novex 3 Minor cardiac
short isoform
18236 5604 46 NM_133379.
4
NP_596870.2
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2.3 TITINOPATHIES
Titinopathy/Titin myopathy is an umbrella term that encompasses wide-ranging skeletal muscle
disorders (Figure 6) and cardiac muscle disorders linked to mutations in TTN gene. Titinopathies
are inherited in both autosomal dominant and recessive fashions. Some well-characterized
titinopathies are late-onset dominant tibial muscular dystrophy, young/early adult-onset recessive
distal titinopathy, limb-girdle muscular dystrophy type 2J, congenital centronuclear myopathy and
early-onset myopathy with fatal cardiomyopathy (Savarese, Sarparanta et al. 2016). Furthermore,
dominant De Novo mutation in TTN, leading to cardiac failure has also been documented (Peled,
Gramlich et al. 2014).
The first TTN mutation (arg to leu replacement in codon 740) was reported in 1999; the authors
proposed that the mutation has a high likelihood of being the underlying cause of hypertrophic
cardiomyopathy (Satoh, Takahashi et al. 1999). Though, the first confirmed association of TTN
mutation to a skeletal muscle disorder was published in 2002; the mutation was described as 11
bp change (AAGTAACATGG→TGAAAGAAAAA/EVTW→VKEK, FINmaj mutation) in the last exon of
TTN, observed in 81 Finnish patients (Hackman, Vihola et al. 2002).
2.3.1 MISSENSE TITINOPATHIES
One of the well-known missense titinopathies is hereditary myopathy with early respiratory failure
(HMERF) that is characterized by debilitating muscles of lower and upper extremities and affecting
respiratory muscles too. The pathogenic mutations in HMERF are located in a single specific exon
(344) and act in a semi-dominant way (homozygous patients have more severe condition than
heterozygous patients) (Palmio, Leonard-Louis et al. 2019).
2.3.2 NONSENSE/TRUNCATED/SPLICING TITINOPATHIES
The term titin truncating variant (TTNtv) can be misapprehended. The literal definition of
truncating variant denotes any change that shortens the normal size of the encoded protein;
however, TTNtv is commonly used to describe TTN splicing, nonsense and frameshift variants,
even though their post-transcriptional outcomes may differ greatly.
In context of skeletal muscle disorders, all TTNtvs are recessive (Ceyhan-Birsoy, Agrawal et al.
2013, Chauveau, Bonnemann et al. 2014, Peric, Glumac et al. 2017), however, in many DCM cases
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TTNtvs seem to act in a dominant fashion (Tabish, Azzimato et al. 2017) . The TTNtvs are prevalent
in DCM cases; approximately 20% of DCM patients have TTNtvs enriched in the A-band region
where all exons are consistently included in the mature transcript (Herman, Lam et al. 2012).
Interestingly, around 2% of the healthy human population has TTNtvs that are likely to be
phenotypically silent possibly because TTNtvs observed in control samples were enriched in exons
not utilized in cardiac N2BA and N2B isoforms (Roberts, Ware et al. 2015), suggesting the
penetrance of causative TTNtvs in general population is significantly low.
It is a well-established genetic fact that the relative abundance of transcripts can be a key factor in
disease manifestation in comparison to a healthy state; such quantitative evaluation has not been
formally done for TTNtvs. Nevertheless, an estimated 0.5% of the general population carries
TTNtvs in exons with PSI >15% that may have the potential to cause DCM (Schafer, de Marvao et
al. 2017).
Figure 6: The figure exemplifies well-known skeletal muscle disorders linked to TTN mutations. The symbols shapes
and colors denote mutation type and the associated phenotype, respectively. The symbols also mark the relative
positions of mutations in particular domains.
Adapted from (Savarese, Sarparanta et al. 2016) with permission from authors.
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3 AIMS OF THE STUDY
This thesis serves two purposes.
1) Characterization of TTN splicing variants to enhance the diagnostic accuracy for patients
with skeletal muscle disorders and to further elaborate on pathogenesis of titinopathies.
2) An attempt to resolve which sequencing method is most suitable for TTN splicing variants
characterization.
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4 MATERIALS AND METHODS
4.1 PATIENTS’ SAMPLES
This study included six patients of confirmed titinopathy i.e. biallelic TTN truncating variants
(detected by NGS MyoCap assay) and a phenotype compatible with the previously reported
titinopathies.
Individuals without any skeletal muscle disorder were recruited as a control group.
All individuals (control subjects and patients) enrolled in this project were thoroughly informed
about the study and have provided written consent. The ethics of the research have been
reviewed by the ethics committee of the Helsingin ja Uudenmaan sairaanhoitopiiri (HUS,
statement number 195/13/03/00/11).
The study has been performed according to the guidelines of The Declaration of Helsinki.
4.2 METHODS
4.2.1 RNA EXTRACTION AND SEQUENCING
Total RNA was extracted and purified from skeletal muscle biopsies using QIAGEN RNeasy Plus
Universal Mini Kit. Deep frozen muscle samples (10-20mg) were placed in lysis tubes E (Analytik
Jena AG) containing steel beads and immediately added 900μl QIAZol lysis reagent. The samples
were homogenized on Tissuelyser (SpeedMill PLUS Analytik jena AG) for 2-5 minutes at 20 Hertz.
The subsequent steps were conducted according to the protocol (QIAGEN RNeasy Plus Universal
Handbook Dec 2014). The optional step of column drying was performed and RNA was eluted in
40μl RNAse free water with second elution using the eluate.
RNA was quantified using Denovix DS-11 Spectrophotometer and qualitative assessment was done
using High Sensitivity RNA ScreenTape (Agilent Technologies) on Agilent 4200 TapeStation system
(Agilent Technologies). The samples were dispatched to The Oxford Genomics Centre for full
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transcriptome analysis (after ribodepletion). RNA enrichment was done using Illumina’s Ribo-Zero
Gold rRNA Removal Kit (Human/Mouse/Rat) and with Illumina´s TruSeq Stranded Total RNA
Library Prep (Human/Mouse/Rat), following the manufacturer´s instructions.
Library preparations underwent a full quality control evaluation and were sequenced with
HiSeq4000 (read length=75bp, paired-end run). An average of ~80 million reads was produced
across all samples. Adapter sequences and low quality bases were removed with fastp. Trimmed
sequences were then mapped with STAR 2.7.0d with index generated from Gencode.v29 human
reference (release date 05.2018, based on ENSEMBL GRCh38.p12).
4.2.2 REVERSE TRANSCRIPTION
The extracted RNA was reverse transcribed as written below in tables 2 and 3.
Table 2: The master mix composition of reverse transcription reaction
Reagent Quantity
10xRT Buffer 2μl
10x Random Primers 2μl
25x DNTP Mix (100 mM) 0.8μl
~100ng/μl RNA Template 10μl
Nuclease-free Water 4.2μl
MultiScribe Reverse Transcriptase 1μl
Total 20μl
Table 3: The thermal conditions and their relative timings for reverse transcription
Phase Temperature Time
Annealing 25°C 10 Minutes
Extension (cDNA synthesis) 37°C 120 Minutes
Reverse-Transcriptase
deactivation
85°C 5 Minutes
Incubation 4°C ∞
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4.2.3 POLYMERASE CHAIN REACTION
The PCR reactions were performed on reverse transcribed cDNA. Primers were designed on
Primer3 software (version 4.1.0, http://primer3.ut.ee/) and ordered from SIGMA-ALDRICH. When
possible (if exon-exon junctions were known), exon-exon junction primers were used for PCR
amplification to circumvent genomic DNA synthesis. The quantities of reagents and timings of
steps are as follows (Tables 4 and 5). The DNA concentrations were checked
spectrophotometrically on Nanodrop (DeNovix DS-11 FX +).
Table 4: The master mix composition of cDNA synthesis
Reagent Quantity
5x GC Buffer 6μl
10mM DNTPs 0.6μl
cDNA 0.5μl
10 μM Forward Primer 1μl
10 μM Reverse Primer 1μl
Milli-Q Water 20.5μl
2U/μl Phusion Hot Start II DNA Polymerase 0.4μl
Total 30μl
Table 5: The thermal conditions and their relative timings for cDNA synthesis in 36 cycles
Phase Temperature Time
Initial Denaturation 98°C 30 Seconds
Denaturation 98°C 10 Seconds
Annealing 60°C 30 Seconds
Elongation 72°C 3 Minutes
Additional 35 cycles of
Denaturation, Annealing and
Elongation.
Approximately 130 Minutes.
Final Elongation 72°C 10 Minutes
Incubation 4°C ∞
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4.2.4 GEL DNA EXTRACTION
(1.5% agarose gel prepared in 0.5x TBE with 5μl of midori green advance [NIPPON Genetics
EUROPE] added)
20μl PCR amplified products intermixed with 4μl of 6x loading dye (Thermo Fischer Scientific) were
run on 1.5% agarose gel submerged in 0.5X TBE Buffer at 110V for 45-60 minutes. The bands
visualized under UV light were excised and DNA was extracted following the manufacturer’s
protocol (MACHEREY-NAGEL NucleoSpin Gel and PCR Clean-up February 2017/Rev. 04) with the
recommended step of heating elution buffer at 70°C. The purified DNA concentration was checked
on Nanodrop (DeNovix DS-11 FX +). The purified DNA was Sanger sequenced by the same primers
used for amplification. The sequences were checked on Sequencher software (Gene Codes
Sequencher 5.3).
4.2.5 PCR CLONING
The PCR fragments were ligated into PCR blunt II-Topo vector (Invitrogen Zero Blunt TOPO PCR
Cloning Kit). The ligation mixture was prepared using 1.5μl PCR product, 0.5μl salt solution, 0.5μl
Blunt II-Topo vector and 0.5μl water with subsequent room temperature incubation for 5 minutes.
Ice thawed vial of chemically competent cells (One Shot TOP10 Chemically Competent E.
coli) was pipetted into the ligation reaction followed by 30 minutes incubation on ice (to attach
cloned vector to the bacterial membrane).
The sample was then heat shocked for 30 seconds at 42°C (increases membrane permeability to
facilitate the transport of vector into cells) and instantly set on ice for 2 minutes (closes membrane
to avoid leaking of cell contents). To obtain maximum transformation efficiency, the cells were
nourished with 250μl of SOC media (Thermo Fischer Scientific) (culturing in antibiotic-free media
before plating allows expression of antibiotic resistance gene) and put on thermo shaker at 300
RPM (revolutions per minute) and 37°C for one hour. The SOC grown cells were plated on
ampicillin (100μg/μl) agar plates and subjected to overnight incubation at 37°C.
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4.2.5.1 OVERNIGHT BACTERIAL CULTURE
The following day 5 sparsely grown colonies were picked and each colony was inoculated in 5ml
L.B media containing 500μg/5μl of ampicillin and allotted another overnight incubation at 37°C
while shaking at 300 RPM under aerobic condition.
4.2.5.2 PLASMID ISOLATION
The plasmids were isolated as detailed in the user manual (NucleoSpin plasmid DNA
purification/Isolation of high-copy plasmid MACHEREY-NAGEL December 2015/Rev. 09). No
recommended steps were performed and plasmids were eluted in 40μl water instead of buffer AE.
The purified plasmid concentration was checked on Nanodrop (DeNovix DS-11 FX +) and sent for
DNA sequencing as per section 4.2.6, with the exception of ExoSAP purification.
4.2.6 SANGER SEQUENCING
The Sanger sequencing was done to ascertain NGS MyoCap detected mutations and on PCR
amplified cDNA. Prior to sequencing, 3μl of ExoSAP-IT was added to 10μl of PCR product followed
by incubation at 37°C (to digest excessive primers and free nucleotides) for 30 minutes and then at
80°C (to inactivate ExoSAP-IT to avoid its action on primers and nucleotides during sequencing) for
15 minutes.
The sequencing reaction was prepared with 1-4μl of DNA (depending on the size of the template),
1.5μl (10 μM) of either forward or reverse primer keeping the final volume to 6μl by adding water.
The samples were sequenced at Institute for Molecular Medicine Finland. The sequences were
analyzed on Sequencher software (Gene Codes Sequencher 5.3).
4.2.7 SINGLE-MOLECULE REAL-TIME SEQUENCING (LONG READS)
The PCR amplified cDNA samples covering particular TTN exons regions and 30 other muscle genes
cDNAs amplified from 5’UTR to 3’UTR region were normalized according to their relative
concentrations and fragments size, and pooled into a single tube. A size selection was performed
to remove amplicons shorter than 700bp to circumvent the frequent sequencing of shorter
fragments over large ones. Library preparation was performed at DNA sequencing and genomics
facility at the Institute of Biotechnology, Helsinki Institute of Life Science (HiLIFE), University of
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Helsinki. The final library was run on PacBio RSII. After trimming the adapters, sequences were
manually visualized and inspected using Integrative Genomics Viewer (IGV).
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5 RESULTS
All TTN variants are described using Meta transcript NM_001267550.1, according to the Human
genome variation society’s (HGVS) recommendations. Exon numbering is according to the Leiden
open variation database (LOVD), i.e. LRG numbering, which is recommended for clinical reporting
and does not correspond to the RefSeq numbering.
5.1 COMPOUND HETEROZYGOSITY
NGS MyoCap assay unveiled the presence of bi-allelic TTN mutations in all patients included in this
study. Most TTN previously unreported variants and VUS were single nucleotide variants (SNVs),
detected in canonical splice sites. In addition, Indel and nonsense mutations were also detected
with variants in canonical splice sites (compound heterozygous state) (Table 8).
All patients had at least one variant in either donor or acceptor splice site. In particular, patients 6
and 1 were identified with bi-allelic variants in canonical splice sites. Patients 2, 5 and 4 were
detected with small insertion or deletion in a compound heterozygous state with a splicing variant.
Lastly, patient 3 was also detected with a splicing variant and a nonsense variant in a compound
heterozygous state. The additional 235 muscle-related genes sequenced in MyoCap were devoid
of any potential causative mutation responsible for the observed phenotype.
The outline of clinical phenotypes of patients is given in table 6, and the methods used for splicing
variants characterization and their results are recapitulated in table 8.
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Table 6: Salient clinical features of patients
6 5 4 3 2 1 Patient
M
/Italy
M
/Spain
M
/Belgium
M
/North
Am
erica
M
/Finland
F/France
Sex/origin
57/Adulthood
47/Early
adulthood)
34/Infancy
14/Birth
-/Birth
-/Early childhood
Age 
at 
last
exam
ination/age
of onset
Difficulty in
w
alking
Distal 
LL 
w
eakness 
and
m
ioglobinuria
Progressive 
m
uscular
w
eakness 
and 
gait
abnorm
alities accom
panied
by frequent falling.
Hypotnia
Hypotonia and
arthrogryposis
Difficulty in w
alking
Sym
ptom
s at onset
Distal>proxim
al
Psoas and
gluteii 4/5; partial
atrophy 
of 
quadriceps,
addcutors 3/5, tibialis anteior
4/5, hanging big toe
Proxim
al UL, proxim
al and distal
LL Distal and proxim
al
Distal LL and neck flexor
Proxim
al> LL distal
M
uscle w
eakness
Distal m
yopathy
Distal m
yopathy
Congenital m
yopathy
Congenital m
yopathy
Congenital m
yopathy
Early 
onset 
recessive
titinopathy
Phenotype
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5.2 RESULTS FROM TRADITIONAL SANGER SEQUENCING METHODS
Patient 1
MyoCap evidenced two previously undescribed variants in this patient: c.15776-1G>T (intron54)
and c.67349-2A>C (intron 319).
PCR reactions were performed using two different combinations of primers (exons 54-56, exons
54-57) on patient and control cDNA samples. The gel electrophoresis analysis confirmed the
amplification of fragments of expected size (approximately 200bp and 250bp) that were also seen
from control samples. The additional larger band visible only from the patient’s sample suggested
a splicing effect due to the abovementioned heterozygous variant.
Direct Sanger sequencing results were enriched of ambiguous base calls, hampering correct
analysis of splicing; thus, the PCR product was rerun on agarose gel electrophoresis, and the
outlined DNA bands were gel-extracted (Figure 7). The subsequent Sanger sequencing revealed 96
nucleotides long intron 54 retention (Figure 8). A similar result was also observed from the
sequencing of cloned PCR product.
Figure 7: The PCR amplification of exon 54 to either 56 or 57. Two bands appear on patient samples show the
heterozygous state, the presence of larger fragments with reference to control fragments is an indication of intronic
retention/splicing defect.
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Direct Sanger sequencing and Gel-extracted DNA sequencing were also performed to characterize
the variant c.67349-2A>C. However, the results were elusive due to low signal to noise ratio. The
cloning of the PCR products (amplified using primers on exons 319-321) with subsequent Sanger
sequencing led to the identification of two discrete splicing effects, entire intron 319 retention
(Figure 9) and first 15 nucleotides loss of exon 320 (Figure 10)
Figure 8: The chromatogram shows mutation c.15776-1G>T in intron 54. The downstream effect is entire 96
nucleotides long intron 54 retention.
Figure 9: The chromatogram shows mutation c.67349-2A>C in intron 319. The downstream effect is entire intron 319
retention.
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Figure 10: The aforementioned mutation executes a different splicing effect resulting in loss of upstream 15
nucleotides of exon 320 and p.(Gln22450Leu).
Patient 2
Patient 2 carries a variant affecting the canonical splice site (c.37040-1G>A intron 179) and 4
nucleotides deletion in exon 358 c.100312_100315del p.(Lys33438Glyfs*4).
Only the variant in intron 179 was selected for characterization because the other variant in exon
358 was not anticipated to alter splicing.
Patient cDNA was PCR amplified with two pairs of primers on different exons (168-182 and 171-
182). The results drawn after PCR cloning and sequencing were inconclusive because exon 179 is
meta-only exon (not expressed in adult muscles) and located in the repetitive region. The reasons
are further elaborated in discussion.
Patient 3
Patient 3 was identified with SNV in allele 1 c.53354G>A exon 279 p.(Trp17785*) that renders a
nonsense effect. The consensus splice site variant in other allele was c.19426+2T>A localized in
intron 67.
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PCR amplified fragments spanning the region from exon 64 to 68 were cloned and sequenced. Two
distinct exon skipping events were seen on chromatogram, the one excluding exon 67 and other
less frequent excluding exon 66 and 67.
Patient 4
From MyoCap, two variants were identified c.35829_35830insA p.(Gly11944Argfs*7) in exon 164
and c.25063+1G>A in intron 87. The splicing variant was selected for sequencing.
PCR amplified fragments spanning the region from exon 85 to 90 were Sanger sequenced, and the
skipping of exon 87 was observed.
Patient 5
Along with a single nucleotide deletion in exon 364 c.107889delA p.(Lys35963Asnfs*9), A variant
affecting the canonical splicing site was observed in intron 26 (c.4646-1G>A). A PCR spanning the
region from exon 25 to 28 was performed. A direct Sanger sequencing showed the skipping of first
14 nucleotides of exon 27.
Patient 6
MyoCap identified two variants in canonical splice sites, in particular, c.107377+2dup in intron 362
and c.54190+1G>A in intron 281.
A PCR (primers in exon 361 and 364) followed by Sanger sequencing revealed the retention of the
first nucleotide of intron 362.
Similarly, a PCR (primers in exons 280 and 283) was performed on cDNA of patient 6 and control.
The most intense band only seen in the patient was extracted, and the subsequent Sanger
sequencing showed the retention of 88 nucleotides long intron 281.
5.3 RESULTS FROM SECOND-GENERATION (ILLUMINA RNA-Seq) AND THIRD-GENERATION
(SMRT) SEQUENCING APPROACHES
Two innovative techniques were implemented to examine the splicing effects. Every single splicing
variant was studied using total RNA-Seq after Ribo-depletion based library preparation, whereas
all except one splicing variant (c.54190+1G>A) were studied using SMRT due to the lack of sample.
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For total RNA-Seq, we analyzed the junction files and manually inspected the TTN region of
interest using IGV.
RNA-Seq confirmed all the previously detected splicing effects from traditional Sanger sequencing.
As expected, the intronic retentions in patients 1 and 6 were clearly seen in IGV due to the
presence of reads in introns 319 and 281, respectively. Conversely, no intronic reads were seen in
samples without a possible splicing variant in these TTN regions. Similarly, no reads provided
coverage on other TTN introns in patients 1 and 6, proving that reads in introns 319 and 281 are
due to their retention and not because of possible DNA contamination.
Interestingly, in patient 4, additional splice events, not identified by the traditional PCR and Sanger
sequencing, were identified. The retention of intron 87 was clearly observed in IGV (Figure 11). No
reads in other TTN introns were observed in this patient, and no other samples showed a coverage
in intron 87, demonstrating the clear mutational effect. Moreover, the skipping of exon 87 alone
and with exon 86 (junction 85-88,) was observed with 1353 and 1536 reads, respectively.
Figure 11: The figure from integrative genomics viewer showing intron 87 retention in patient 4. Out of total 8018
reads, 7598 reads support the variant call c.25063+1G>A (In figure shown by nucleotide T because of TTN location on
minus strand).
Similarly, in patient 6 two additional abnormal splicing events due to the variant c.54190+1G>A in
intron 281 were observed; the loss of last 7 and last 130 nucleotides of exon 281 was supported by
966 and 1890 reads, respectively.
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By further analysis of exon junction files, we also tried to quantify aberrant splicing events of exon
skipping and loss of nucleotides (Table 7).
In patient 1, 23317 reads supported the loss of upstream 15 nucleotides of exon 320 and were
more than twice the number of reads supporting exon 319-320 junction, which supposedly came
from wild type allele.
In patient 3, the skipping of exon 67 (a junction 66-68) was explicitly observed with 14648 reads
from RNA-Seq results. Reads supporting exclusion of exon 66 along with exon 67 (junction 65-68)
were only 544 in number. In contrast, 22001 reads supported the exon 66-67 junction.
In patient 5, the loss of first 14 nucleotides of exon 27 was confirmed by 1183 reads, the number is
approximately 1/3 of reads supported exon 26-27 junction (Table 7).
Finally, in patient 6, 10334 reads from RNA-Seq results supported the retention of the first
nucleotide of intron 362 from IGV (10312 supported the normal junction 362-363).
SMRT analysis confirmed the previous PCR-based results but, for example, failed to identify the
skipping of exon 87 and 86 along with 87 in patient 4 where only the intronic retention was
detected. The table below enumerates RNA-Seq reads from splicing variants.
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Table 7: RNA-Seq Reads (Exon-exon junctions and loss of nucleotides, reads of interest are
written in bold)
Patient Splice variant Reads Donor
exon
Acceptor
exon
Genomic coordinates
1 c.67349-2A>C
(int319)
23317 319 #N/A 2:178579833-178579939 (loss of
first 15 nucleotides of exon 320)
9570 319 320 2:178579848-178579939
2 c.37040-1G>A
(int179-metaonly)
undetected
12 179 189 2:178657767-178662142
19 179 180 2:178662028-178662142
3 c.19426+2T>A (int67) 16145 67 68 2:178728397-178728500
14648 66 68 2:178728397-178728891
22001 66 67 2:178728778-178728891
544 65 68 2:178728397-178729288
4 c.25063+1G>A
(int87)
30470 87 88 2:178717810-178717943
42988 86 87 2:178718221-178718322
1353 86 88 2:178717810-178718322
1536 85 88 2:178717810-178718695
43019 85 86 2:178718600-178718695
5 c.4646-1G>A (int26) 3355 26 27 2:178777317-178777420
1183 26 #N/A 2:178777303-178777420 (Loss of
the first 14 nucleotides of exon
27)
6 c.54190+1G>A
(int281)
23781 281 282 2:178604898-178604987
966 #N/A 282 2:178604898-178604994 (loss of
last 7 nucleotides of exon 281)
1890 #N/A 282 2:178604898-178605117 (loss of
last 130 nucleotides of exon 281)
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Table 8: A concise description of splicing variants and their results obtained from different
methods.
Patient Splicing
Variant(s)
Results Methods Additional Information
1 c.67349-2A>C
(Intron 319)
c.15776-1G>T
(Intron 54)
Intron 319
retention, loss of
first 15 nucleotides
of exon 320.
Intron 54 retention.
Direct Sanger sequencing,
Sanger sequencing on Gel
extracted DNA bands,
Sanger sequencing on
cloned PCR products, RNA-
Seq and SMRT sequencing.
2 c.37040-1G>A
(Intron 179)
Inconclusive (Meta
only).
Direct Sanger sequencing,
Sanger sequencing on
cloned PCR products, RNA-
Seq and SMRT sequencing.
RNA-Seq data showed
negligible number of
reads supporting exon
179 inclusion in adult
isoform (N2A). In trans
variant
c.100312_100315del
3 c.19426+2T>A
(Intron 67)
Skipping exon 67,
skipping exon 66
with 67.
Sequencing on cloned PCR
products, RNA-Seq and
SMRT sequencing.
In trans variant
c.53354G>A
4 c.25063+1G>A
(Intron 87)
Skipping exon 87,
skipping exon 86
with 87 and intron
87 retention.
Direct Sanger sequencing,
RNA-Seq and SMRT
sequencing.
Skipping of exon 86 with
87 and intron 87
retention were not seen
in Sanger sequencing and
no skipping event was
identified from SMRT.
All splicing events were
detected from RNA-Seq.
In trans variant
c.35829_35830insA
5 c.4646-1G>A
(Intron 26)
Loss of the first 14
nucleotides of ex 27.
Direct Sanger sequencing,
RNA-Seq and SMRT
sequencing.
In trans variant
c.107889delA
6 c.54190+1G>A
(Intron 281)
c.107377+2dup
(Intron 362)
Intron 281
retention, loss of
last 7 and last 130
nucleotides of exon
281.
Retention of first
nucleotide of intron
362.
Direct Sanger sequencing,
Sanger sequencing on Gel
extracted DNA bands, RNA-
Seq and SMRT sequencing.
Loss of last 7 and last 130
nucleotides of exon 281
was only observed from
RNA-Seq results.
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6 DISCUSSION
6.1 IMPORTANCE OF CHARACTERIZING SPLICING VARIANTS
Alternative splicing is a natural phenomenon to produce multiple gene isoforms/splice variants by
a single gene. The transcripts if diverge from normal splicing patterns may prompt an abnormal
function or undergo degradation via NMD in certain circumstances (Ge and Porse 2014).
Although, the enhanced efficiency of genetic tests as a result of the introduction of massively
parallel sequencing technologies in clinical diagnosis is phenomenal; the number of variants of
uncertain significance has also increased substantially (Di Resta, Galbiati et al. 2018).
The characterization of titin splicing variants poses a challenge primarily due to its sheer size,
repetitive regions, meta-only exons and highly modular structure (Savarese, Maggi et al. 2018).
However, the characterization of variants is of profound importance in order to make an accurate
diagnosis, especially in patients manifesting less distinct phenotypes with a possibility of
numerous candidate muscle genes involved.
Furthermore, the characterization of variants is essential to distinguish between benign and
causative variants to their relative extents (semi-dominant), which eventually could be useful for
personalized medicine approach as well and to limit the number of variants of uncertain
significance.
In this project, we studied six patients of skeletal muscle disorders, identified with TTN potential
causative mutations in NGS MyoCap assay. The downstream effects of splicing were analyzed with
different sequencing techniques, including third-generation sequencing called SMRT long reads,
which provides an average read length of 10-16 kb (Ardui, Ameur et al. 2018).
6.2 THE COMPLEXITY OF ALTERNATIVE SPLICING PATTERNS IN TTN GENE
Due to the vast number of exons in TTN gene, exon-exon junctions that are not part of adult
canonical isoforms are commonly observed and may not necessarily indicate aberrant splicing,
especially in case of meta-only exons that are frequently skipped as part of normal splicing
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pathway in adult isoforms. This draws attention towards the fact that whether a particular exon
skipped in a patient is commonly skipped in healthy population or is a consequence of splicing
defect. The number of reads supporting specific exon exclusion/inclusion in healthy population in
comparison to a patient as a result of splicing variant may explain the splicing defect, (RNA-Seq
data provides a good semi-quantitative estimation of the different splicing events). Besides that,
junctions entering and exiting a particular exon are also often different (exon usage).
6.3 INTERPRETATION OF RESULTS
TTN splicing mutations detected in a compound heterozygous state (second allele with a different
causative TTN mutation) were analyzed.
In patient 1 first splicing variant c.15776-1G>T (Intron 54) causes retention of intron 54, which has
multiple stop codons and as a consequence mRNA is likely to be degraded via NMD pathway. This
explanation is corroborated by previous data (Schafer, de Marvao et al. 2017), which describes
that most TTNtvs are degraded by NMD. Thus, this will effectively be a null allele. Nonetheless, a
small amount of truncated protein synthesis is expected given the fact that the NMD pathway is
elicited following the first round of translation (Plant, Wang et al. 2004).
The second variant c.67349-2A>C (Intron 319) prompts two distinct ASEs (skipping of upstream 15
nucleotides of exon 320 and retention of intron 319). Since intron retention also triggers NMD
because of PTCs occurrence within its 90 nucleotides long sequence; the skipping event (loss of
one FNIII domain) would result in a near full-length titin and is apparently the reason of affected
individual’s survival as well the reason of disease phenotype.
For the second variant, the RNA-Seq results present more reads of 15 nucleotides skipping effect,
apparently splicing machinery on this variant frequently uses cryptic splice site in exon 320 before
splicing exon 320 to 321. (2262 reads showed the intronic retention from IGV [data not shown
here] versus 23317 reads supported the loss of 15 nucleotides).
In the patient 2, the variant c.37040-1 G>A (Intron 179) was detected in NGS MyoCap assay but
the RNA and cDNA sequencing results were not decisive because the exon 179 is only expressed in
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meta-transcript (during embryonic life) and has extremely low or no expression in any adult main
isoform.
PCR amplification of cDNA (if there is any expression of exon 179) using normal primers is difficult
because identical sequences are present in exons 188 and 197, also junction primers are difficult
to design in this particular region because junctions of flanking exons are not known as they are
also meta-only exons and share repeated sequences with exons in vicinity (Figure 12). Moreover, if
we assume that variant causes intron 179 retention, PCR amplification in this region would still be
problematic because introns 179,188 and 197 also have identical sequences.
Figure 12: The figure exhibits the array of exons (most of these exons are only expressed in fetal titin) in the meta-only
repeated region. The exons with identical sequences are marked with the same color and the numbers superscripted
with asterisk signify exons that are inconsistently included in adult N2A isoform.
The pathophysiology mechanism of patient 2 is relatively difficult to characterize. Since the
identified variant lies in meta-only exon, the disease onset was before birth but the muscle
weakness persists throughout life without progression despite the fact that meta-transcript/fetal
titin is replaced by adult skeletal titin isoform (Ottenheijm, Knottnerus et al. 2009).
If the transcripts generated from the allele harboring splicing mutation in intron 179 were
subjected to degradation via NMD pathway due to splicing defect, the allele would be null, and the
patient would not have survived until birth because titin kinase domain would be missing in
homozygous state (the second variant c.100312_100315del p.(Lys33438Glyfs*4) creates PTC
before titin kinase) which results in sarcomere disassembly (Gotthardt, Hammer et al. 2003).
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Alternatively, if the mutation in intron 179 does not direct transcripts to NMD then underlying
cause of disease could be the other splicing defect e.g. exon skipping or in-frame deletion, but this
explanation is plausible for embryonic development as exons adjacent to intron 179 are only
expressed in prenatal life and mutation in intron 179 is likely irrelevant for aberrant splicing in
adult isoform. Nevertheless, meta-transcript only mutations have been postulated to have an
impact on the structure and/or function of one or more unidentified titin developmental isoforms
(Oates, Jones et al. 2018).
By the reason that skeletal muscles have a regenerative property (Carlson 1973), and the adult
isoform is normal, the description of rudimentary is rather improbable in this particular case.
These explanations are mere speculations and no coherent description can be given without
analyzing TTN isoforms from fetal muscles. Until now, the only clear genotype-phenotype
correlation is that a mutation in meta-only exons causes specific early-onset (prenatal-onset) joint
contractures called arthrogryposis (Fernandez-Marmiesse, Carrascosa-Romero et al. 2017), which
is the attributed phenotype of this patient.
In patient 3, the first variant c.53354G>A p.(Trp17785*) in allele 1 generates PTC; hence this would
be a null allele.
The production of slightly shorter protein (exon 67 skipped/loss of 93 amino acids) is expected
from the second allele. It is to be noted that the higher number of reads in RNA-Seq data
supporting the canonical exon 66-67 junction is supposedly from transcripts synthesized by the
allele 1 that are degraded by NMD and their absence is contributing factor of disease phenotype.
The splicing variant also causes a secondary effect i.e. skipping of exon 66 with 67, which is
relatively a minor splicing event (supported by 544 reads, see table 7) but shows that splicing
mutation may render its effect on more than a single exon in proximity. Both exons 66 and 67 are
symmetric, and their exclusion does not alter the reading frame.
In Patient 4, the first variant c.35829_35830insA p.(Gly11944Argfs*7) of allele 1 in exon 164
generates PTC resulting from frameshift effect. However, the exon 164 is meta-only exon and
would have directed the transcripts to undergo NMD only when included (mainly during prenatal
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life). An attempt to elucidate the pathophysiology mechanism would be based mainly on
conjectures as described for the case of patient 2.
The variant c.25063+1G>A in allele 2 causes intron 87 retention (8018 reads support intron
retention, figure 11) and skipping of exons 86 and 87.
The skipping is quantitatively not a major event compared to reads supporting their inclusion
(Table 7); however, the reads from other samples showed very low or no skipping of exons 86 and
87, which raises the question whether this skipping event is functionally relevant to the disease.
The transcripts with intron 87 retained would be degraded via NMD because of PTC, whereas
transcripts with exon(s) skipped would cause in-frame deletion of Ig-like domain(s) from the I-
band region.
It is noteworthy that the higher number of reads from RNA-Seq data supporting exon 86-87 and
87-88 junctions (Table 7) is presumably from transcripts produced by allele 1, which are equivalent
of wild type isoforms in adult life. We surmise that most transcripts from both alleles were
targeted by NMD during embryonic life, though the patient survived because of exon 87 skipping
event which intrinsically saved transcripts from degradation.
The splicing variant c.4646-1G>A in patient 5 prompts the loss of first 14 nucleotides of exon 27 by
activating cryptic splice site. This out of frame effect p.(Ala1549Glyfs*21) will consequently trigger
NMD and this would be a null allele.
The second variant c.107889delA p.(Lys35963Asnfs*9) also generates PTC as a consequence of
frameshift, but in this particular case the transcripts are very unlikely to be targeted by NMD
pathway as the premature stop codon appears in the last exon, as it has been hypothesized based
on the results of previous studies that distal M-Band/C-terminal of titin harboring PTC does not
undergo NMD degradation (Deo 2016).
Furthermore, if NMD targeted the transcripts generated from both alleles, the patient would not
have survived until postnatal life. Thus, the underlying reason for the abnormal function of protein
is a frameshift effect and a very small truncation, combined both would distort the M10 domain
structure and are likely to obstruct the binding of proteins such as Obscurin, Obscurin-like 1 and
Myospryn (Evila, Vihola et al. 2014).
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Lastly, in patient 6 three distinct splicing effects were seen as a result of the first variant
c.54190+1G>A in intron 281 (Table 8). Irrespective of their differences, all transcripts generated
from the allele would be degraded by NMD as all three events cause disruption in the frame.
The second splicing variant c.107377+2dup causes retention of first nucleotide of intron 362 and
induces PTC p.(Pro35793Argfs*4) but the transcripts are likely to evade NMD degradation due to
the relative position of PTC (intron 362) and would result in production of stable truncated titin, as
demonstrated by (Carmignac, Salih et al. 2007) that C-terminus titin deletion downstream of titin
kinase domain (TK encoded by exon 359) still results in titin incorporation into sarcomere.
The current data on pathogenesis of titinopathies is scant, and data interpretation is often
complicated. Mis-splicing causing premature stop and NMD is most likely pathogenic. The
situation is more complex when a splicing variant results into a small in-frame deletion and a
slightly shorter titin that is still near full-size protein. In such case, a mutation (small in-frame)
could be pathogenic or well-tolerated.
6.4 GENOTYPE- PHENOTYPE CORRELATION
Since the genotype-phenotype correlation in above patients is precisely indicative of titinopathies;
it does not rule out the possibility of other muscle genes acting as “genetic modifiers” for these
phenotypes, and to which extent genetic modifiers (if any) may correlate with titinopathies
phenotype. Titin itself acting as a genetic modifier in DCM has been proposed (Roncarati, Viviani
Anselmi et al. 2013).
Even though the phenotypes of our patients are compatible with titinopathies, segregation studies
are necessary for outright genotype-phenotype correlation (Savarese, Maggi et al. 2018), which
we were unable to perform due to unavailability of family data and a small cohort of samples.
The explicit correlation, evident from our experimental data is that all patients have quasi-
normal/near full-length (N2A) titin, demonstrating that a near full-length titin is vital for survival
until birth. Furthermore, in patients 1-4 congenital or early childhood onset phenotypes were
consistent with variants in A-band or I-band, whereas early adult/adult-onset phenotypes were
observed when the variant is positioned in one of the last exons (patients 5 and 6). Furthermore,
we reaffirm the already reported association between arthrogryposis and meta-only mutations.
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Lastly, the disease onset with respect to the relative location of a variant in M-band of titin is not
firmly established, and the variable ages of onset have been observed (manuscript in preparation).
6.5 LIMITATIONS
Considering the low prevalence of titinopathies (no official reports on disease prevalence
available) and procuring muscle biopsies presents numerous obstacles, the number of samples
analyzed in this project was fairly low. To overcome hindrances in obtaining muscle samples, we
performed minigene splicing assay for the last 4 TTN exons (M-band) in HeLa cells. Minigene
splicing assay is an experimental approach to transfect gDNA fragments and study splicing in
mammalian cell lines.
Our plan was to observe constitutive splicing and in subsequent experiments perform site-directed
mutagenesis to introduce mutations in canonical and cryptic splice sites to study the effects of
potential splicing mutations. The splicing effects in TTN I-band studied via minigene splicing assay
using HEK-293 and HeLa cell lines have been reported before (Ceyhan-Birsoy, Agrawal et al. 2013,
Li, Guo et al. 2013). Nevertheless, we were unable to obtain any splicing results from HeLa cell
line. As the genomic landscape of HeLa cell line is chaotic (Landry, Pyl et al. 2013), we speculate
that HeLa cells don’t express all splicing factors necessary for TTN M-band splicing. Upon literature
search, we could not find any source reporting minigene splicing assay performed on TTN M-band
region.
Our future intent is to select a cell line for minigene splicing assay that closely resembles human
muscle cells such as C2C12 (mouse muscle progenitor cell line).
Another limitation of this study is that we could not attain results from variants located in meta-
only repeated region, therefore their role in disease remains obscure, however, as clearly
demonstrated in this thesis, the study of splicing variants affecting meta-only exons is not feasible
using an adult muscle and probably requires a fetal tissue or use of a minigene splicing assay.
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6.6 COMPARATIVE ANALYSIS OF DIFFERENT SEQUENCING METHODS TO STUDY TTN SPLICING
VARIANTS
Five different sequencing methods were used in this project to characterize splicing variants. The
pros and cons of methods are listed in table 9.
Among the traditional methods, direct Sanger sequencing was most convenient though many
times the results were vague because of high background noise; thus, the PCR samples had to be
gel extracted or cloned prior to sequencing. To a lesser extent, similar problem of low signal to
noise ratio was encountered with gel extracted DNA sequencing. Nonetheless, PCR cloning, a
much more complex and expensive procedure, always provided clear and unambiguous results.
Illumina RNA-Seq was chosen as a high-throughput sequencing approach as it has been reported
as a superior technique over other transcriptomic approaches (Wang, Gerstein et al. 2009) and is
apparently the most promising for TTN splicing variants analysis because of its high data
throughput that enabled us to detect the highest number of splicing events, including minor
splicing events and quantify them.
Regarding the efficacy of SMRT sequencing, one of the splicing effects (observed in RNA-Seq) was
not seen in SMRT sequencing because of low reads count. This may be due to some technical
aspects: a) pooling of several other PCR products that minimized the number of TTN reads in our
results; b) we sequenced PCR fragments with a size range between 700 bp and 2000 bp, the
smaller sized fragments were sequenced more often and generated higher number of reads than
larger fragments. In our perspective, also considering the additional preliminary data not included
in present thesis, SMRT can be very useful for routine diagnostic analysis of large individual
transcripts such as those of dystrophin that nowadays are often sequenced via Sanger sequencing
method using dozens of overlapping fragments.
Considering the intricacies of size and structure of TTN, An RT-PCR-based method to analyze the
full-length transcript is not recommended. In our experience, whole transcriptome (Illumina RNA-
Seq) is the most feasible and exhaustive approach to study TTN transcripts in patients with or
without previously identified TTN variants.
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Table 9: The table summarizes OUR EXPERIENCE with following sequencing techniques
6.7 FUTURE PROSPECTS
Taking into account the immense size of TTN with 364 exons and the advancements in high-
throughput sequencing technologies, it is logical to presume that the landscape of TTN splicing
variants will greatly increase in the near future.  However, the bigger hurdle in translation of
current knowledge into clinical practice resides in variant classification rather than mere variant
identification (Quintáns, Ordóñez-Ugalde et al. 2014). A study adjudged that 122 out of 460
mutations listed in literatures for severe childhood recessive diseases were common SNPs and
sequencing errors (Bell, Dinwiddie et al. 2011); this underscores the significance of proper variant
characterization and a more comprehensive approach for that (see conclusive remarks).
In addition, all patients analyzed in this project carried splicing variants in canonical splice sites;
the higher uncertainty is associated with the characterization of splicing variants out of canonical
splice sites and deep intronic/exonic variants mainly because variants in canonical splice sites are
well known to disrupt normal splicing (Spurdle, Couch et al. 2008), and bioinformatics programs
do not have high accuracy in predicting cryptic splice variants (Tang, Prosser et al. 2016), which as
well drives attention towards the need for higher accuracy in silico prediction tools.
Direct
Sanger
sequencing
Gel DNA
sequencing
Pcr cloning
sequencing
Illumina RNA
seq
SMRT
Strengths High
accuracy
High
accuracy
High
accuracy,
clear
results
High
throughput and
high accuracy,
cost effective
Long reads
(high
resolution)
Drawbacks Noisy data,
ambiguous
base calls
Noisy data,
ambiguous
base calls
High-cost Short reads
(low coverage),
data analysis is
tricky/mapping
issues.
Single read
is error
prone, Low
number of
reads.
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In a broader perspective, comprehensive studies are needed for proper evaluation of all structural
domains of titin and their possible protein-protein interactions sites missed upon in-frame
deletion, such data will provide deep insights into functional roles of individual titin domains and a
vast understanding on pathogenesis of titinopathies.
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7 CONCLUSIVE REMARKS
Based on guidelines and criteria established by American college of medical genetics and genomics
for Mendelian disorders, a sequence variant can be classified as 1) pathogenic 2) likely pathogenic
3) variant of uncertain significance 4) likely benign 5) benign.
We used the online variant interpretation tool developed by (Kleinberger, Maloney et al. 2016),
which is based on ACMG guidelines and classified the variants accordingly.
Table 10: The classification of TTN splicing variants studied
Variant Clinical significance Evidence
c.15776-1G>T (intron 54) Pathogenic (Ia) PVS1, PS3, PP4
c.67349-2A>C (intron 319) Pathogenic (Ia)
Likely pathogenic (II)
PVS1, PS3, PM3, PP4,
PS3, PM3, PM4, PP4
c.37040-1G>A (intron 179) VUS
c.19426+2T>A(intron 67) Likely pathogenic (II) PS3, PM3, PM4, PP4
c.25063+1G>A (intron 87) Pathogenic (Ia)
Likely pathogenic (II)
PVS1, PS3, PP4
PS3, PM4, PP4
c.4646-1G>A (intron 26) Pathogenic (Ia) PVS1, PS3, PP4
c.54190+1G>A (intron 281) Pathogenic (Ia) PVS1, PS3, PP4
c.107377+2dup (intron 362) Likely pathogenic (II) PS3, PM3, PM4, PP4
The PVS1 criterion matched for the last variant (c.107377+2dup) but was replaced by PM4
because of the farther downstream position of the variant that is expected to cause small
truncation without loss of function (LOF); ACMG also advises to exercise caution for such variants
interpretation.
The variants rendering distinct splicing effects were classified as both pathogenic and likely
pathogenic because of their disparate anticipated outcomes.
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Finally, all variants classified as pathogenic include the PS3 criterion that requires functional
studies of RNA or protein supportive of the damaging effect. However, functional studies merely
at RNA and protein level have been questioned for variant classification of MYH7 gene, in the
related panel discussion, the experts decided that strong functional evidence can only be
established by analysis of a mammalian variant-specific knock-in model for MYH7 gene (Kelly,
Caleshu et al. 2018).
Likewise, deeming the complexity of TTN, the interpretation of pathogenic effects is not
straightforward as of other average-sized genes and it is difficult to infer pathogenicity in TTN
solely on the basis of transcriptome studies and may require a variant-specific knock-in model to
achieve 100% certainty.
As for which method is most suitable for TTN splicing variants characterization, our results
illustrate that among the methods we used, no single method is ideal (though RNA-Seq is very
efficacious) and it seems that combination of high-throughput and high-resolution (long 
reads) sequencing approaches is very propitious.
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11 APPENDICES
PRIMERS SEQUENCES TARGETED VARIANTS
25F GGTAGACCTATGCCAGAGACGTTC c.4646-1G>A
28R CCTCCAGTCACGCATTCTTACTT
54F AGCTTTTCCAATGGTGTTGCAGT c.15776-1G>T
56R CGACAAGTGAAATTCCCTGCATCA
57R AGAACATCCTTTGAGCCGGGTT
64F TGCCAGGGTAGAAAATAGTGG c.19426+2T>A
69R GTCGCCCAGGTTTCACTAGGAA
85-86F (Junction primer) GTGAAAGAACCAGCCACCTTTGT c.25063+1G>A
89-90R (Junction primer) GTTCTTGTACACCCAGCTGAGC
170F (Repetitive region) GAGATTATCCCTGAAAAGAAAGTGTCG c.37040-1G>A
182R (Repetitive region) CTTTTGTGGGTGGCACTTCAGG
280F TCACACTTGACTGGAAAGAGCCC c.54190+1G>A
283R AGATTTCTTGGTGGGGATGGGC
319F ACTTCTTCCGAGTGTTTGCTGA c.67349-2A>C
321R TTATGGGGATCTTAAGCCGGAAGTT
361F GATGCTCCAGCCTTCATCTC c.107377+2dup
364R (CATGTTACTTCTGGGGTAGGC)
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GENES ANALYZED IN MYOCAP ASSAY
ABHD5 DES ITPR1 MYL12A
ACADS DMD KBTBD10 (KLHL41) MYL12B
ACADVL DMPK KBTBD13 MYL2
ACTA1 DNAJB6 KBTBD5 (KLHL40) MYL3
ACTN3 DNM2 KCNE1 MYL4
ACVR1 DOLK KCNE3 MYL5
AGL DPAGT1 KCNJ2 MYL6
AIFM1 DPM1 KCNQ1 MYL6B
ALG13 DPM2 KLHL9 MYL7
ALG14 DPM3 KY MYL9
ALG2 DYSF LAMA2 MYLIP
ANO5 ECEL1 LAMB1 MYLK
ATP2A1 EMD LAMP1 MYLK2
B3GALNT2 ENO3 LAMP2 MYLK3
DCST24 ETFA LARGE MYLK4
DCST23 ETFB LDB3 MYLPF
DCST22 ETFDH LDHA MYOM1
DCST21 EXOSC3 LDHB MYOM2
DCST20 FBN2 LIFR MYOM3
DCST19 FBXO32 LIMS2 MYOT
DCST18 FHL1 LMNA MYOZ1
DCST17 FHL2 MARS MYOZ2
DCST16 FKRP MATR3 MYOZ3
DCST15 FKTN MBNL1 MYPN
DCST14 FLNC MBNL2 NBR1
DCST13 GAA MBNL3 NEB
DCST12 GATM MEGF10 NEBL
DCST11 GBE1 MSTN NEFL
DCST10 GMPPB MTM1 NTRK1
DCST9 GNB4 MTMR14 OBSCN
DCST8 GNE MYBPC1 OBSL1
DCST7 GOSR2 MYBPC2 PABPN1
DCST6 GSN MYBPC3 PDK3
DCST5 GTDC2 (POMGNT2) MYH1 PDLIM3
DCST4 GYS1 MYH2 PDLIM5
DCST3 HEXB MYH3 PDLIM7
DCST2 HK1 MYH4 PFKM
DCST1 HSPB8 MYH7 PGAM2
DCST0 ISCU MYH8 PGK1
DCST1 ISPD MYL1 PGM1
DCST2 ITGA7 MYL10 PLEC
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PLEKHG4 TMEM55B
PLEKHG5 TMOD3
PLN TNNC1
PNPLA2 TNNC2
POLG TNNI1
POMGNT1 TNNI2
POMT1 TNNI3
POMT2 TNNT1
PRKAG2 TNNT3
PTPLA TNPO3
PTRF TNXB
PYGM TOR1AIP1
QDPR TPM1
RBCK1 TPM2
RYR1 TPM3
SBF1 TPP1
SCN4A TRAPPC1
SEPN1 TRAPPC11
SGCA TRIM32
SGCB TRIM54
SGCD TRIM55
SGCG TRIM63
SGK196 (POMK) TTN
SLC22A5 TTR
SLC25A20 UBA1
SLC5A2 VCP
SMCHD1 VMA21
SOX10 VRK1
SQSTM1
SRF
STAC3
STIM1
STIM2
SYNE1
SYNE2
SYNE3
SYNPO2
TCAP
TFG
TIA1
TIAL1
TMEM43
TMEM5
TMEM55A
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cDNAs POOLED WITH TTN SAMPLE IN SMRT RUN
ACTN2
ANO5A
ANO5B
CAPN3
DES
DYSF
ENO3
FLNC
GNE
HSPG
ITGA7
LDB3
MYH7
POPDC2
SACS
SGCG
SQSTM1
STAC3
TIA1
TNNT1
TPM2
TPM3
VCP
CRYAB
FXR1
MATR
MBLN1
MYPN
MACF1
SGCB
SMPX
